Market News & Trends
Dunad Therapeutics Enters Strategic Collaboration With Novartis to Develop Next-Generation Oral Targeted Protein Degrader Therapies
Dunad Therapeutics recently announced it has entered a strategic collaboration and license agreement with Novartis to generate orally bioavailable covalent and protein degrading small molecule drugs…..
Strategic Investment in Small Molecule API Development Creates New Flow Chemistry Centre of Excellence at CordenPharma Chenôve
CordenPharma recently announced the completion of a Phase 1 strategic investment to create a Flow Chemistry Centre of Excellence at its CordenPharma Chenôve facility, near…
Two New Studies Demonstrate In Vitro Bioactivity Potential of Micronized Dehydrated Human Amnion Chorion Membrane to Prevent Pathological Processes Underlying Osteoarthritis & Tendinopathy
MiMedx Group, Inc. recently announced two peer-reviewed studies investigating the use of micronized dehydrated human amnion chorion membrane (mdHACM) for the treatment of debilitating conditions…
Coherus & Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. recently announced the US FDA has accepted for review the Biologics License Application (BLA) for toripalimab in combination with….
Novavax & Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Novavax, Inc. and Serum Institute of India Pvt. Ltd. (SII) recently announced that the National Agency of Drug and Food Control of the Republic of…
Catalent Further Expands Clinical Supply Network With New Facility in San Diego
Catalent recently announced the opening of a new facility in San Diego in response to increased demand from pharmaceutical and biopharmaceutical customers for integrated development,…
Gattefossé Expands its Offer With the Launch of Three New Pharmaceutical Excipients
Gattefossé, supplier of specialty ingredients for the health and beauty industries, announces the launch of three new pharmaceutical ingredients: Labrafac™ MC60 and Gelucire® 59/14, for the for oral administration route and Emulfree® Duo….
Nemera Launches UniSpray, its Unidose System Primarily for Systemic-Acting Drug Administration
Nemera has a proven track record in developing and manufacturing complex Ear Nose and Throat solutions. In line with clear growing market interest in unidose system coupled with promising advantages that nasal route could….
Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of its mRNA Cytomegalovirus (CMV) Vaccine
Moderna, Inc. recently announced the first participant has been dosed in the Phase 3 pivotal registration study of mRNA-1647, the Company’s cytomegalovirus (CMV) vaccine candidate. This…
Ocugen, Inc. Announces Submission of IND to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate
Ocugen, Inc. recently announced that it has submitted an Investigational New Drug application (IND) with the US FDA to evaluate the COVID-19 vaccine….
Aptinyx Completes Enrollment in Phase 2b Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
Aptinyx Inc. recently announced the completion of enrollment in the company’s ongoing Phase 2b study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy….
Halberd Files Provisional Patent on Breakthrough Obesity Treatment
Halberd Corporation recently announced the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood…
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA (pembrolizumab) in Patients With Melanoma
Evaxion Biotech A/S recently announced it has entered into a clinical trial collaboration and supply agreement with subsidiaries of Merck & Co., Inc., Kenilworth, NJ,…
TCR² Therapeutics Announces Clinical Trial Collaboration Agreement With Bristol Myers Squibb
TCR2 Therapeutics Inc. recently announced a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate gavo-cel in combination with Opdivo (nivolumab) and Yervoy (ipilimumab)…
Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy & Powerful Potential of Antigen-Independent Tumor Targeting
Cybrexa Therapeutics recently announced favorable early Phase 1 data for its lead therapeutic candidate, CBX-12 (alphalex-exatecan). The initial data show robust….
Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. recently announced the last participant has completed the 26-week dosing period and 30-day safety follow up visit in the GEM-3 study, Krystal’s…
Berkeley Lights Announces GSK Acquires Third Beacon Optofluidic System to Expand Antibody Therapeutics Development
Berkeley Lights, Inc. recently announced GlaxoSmithKline (GSK) has purchased an additional Beacon Optofluidic system to expand its antibody therapeutics capacity. The new Beacon system will….
Catalent's Investment in Expanding its State-of-the-Art Gene Therapy Commercial Manufacturing Campus Increases to $360 Million
Catalent recently announced a $230-million expansion project to add three further commercial-scale viral vector manufacturing suites and associated support facilities and services at its gene…
Micropore Appoints New Commercial Director
UK-based Micropore Technologies has recently appointed Denis Smit, Invista’s former Head of New Business Development, to the role of Commercial Director to lead their….
Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever System in Pulmonary Embolism Patients
Inari Medical, Inc. recently announced planned enrollment of the PEERLESS trial. PEERLESS is a new randomized controlled trial (RCT) comparing the clinical outcomes of patients with intermediate-high risk pulmonary embolism….
